KRAS and neoplasm: In this model, activation of cancer cells carrying the mutated KRAS by IL-4 and IL-13, which were secreted by the Th2 cells present in the tumor microenvironment, triggered the JAK1-STAT6-MYC pathway that in turn activated glycolysis crucial for tumor progression.